At least four novel applications under review at the US Food and Drug Administration rely on clinical trials conducted in China, giving the FDA’s longstanding policy on applications based solely on foreign clinical data what may be its most extensive workout yet.
Chinese regulators have been tightening standards on clinical trial conduct after the country’s landmark 2017 decision to join the International...